BioSpace News Archive

Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical med-chem company specializing in the research and development of potent novel monotherapeutics, announced today that the Company has been issued Australian Patent AU2015204609B2 (the “Patent”) specific to “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy.” This patent grant marks the seventh paten

E25Bio , innovators of rapid diagnostic tests, announced today that it has raised a $2 million financing from Khosla Ventures. Founded in 2018 and based out of The Engine at MIT, the company develops technology for rapid diagnosis of dangerous infectious diseases such as dengue, zika, and now the novel coronavirus.

DXC Technology (NYSE: DXC) today introduced an advanced Patient-Centered Care solution, a customizable and personalized-health offering that gives healthcare providers the technology to meet the high expectations of today’s patients — without sacrificing cost containment and clinician satisfaction.

TOMI Environmental Solutions, Inc.® (“TOMI”) (OTCQB:TOMZ), is a global company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist products - a hydrogen peroxide-based mist and fog composed of ionized Hydrogen Peroxide (iHP).

TB12, the performance lifestyle brand co-founded by six-time Super Bowl champion Tom Brady and business partner Alex Guerrero, today announces Tara McRae as the company’s Chief Marketing Officer.

Blue Shield of California is offering a new digital tool to its network hospitals at no additional cost to help them triage the influx of patients seeking advice on coronavirus (COVID-19) or other medical care.

Pfizer Inc. (NYSE:PFE) announced today that JADE COMPARE (B7451029) met its co-primary efficacy endpoints. The Phase 3 study evaluated the safety and efficacy of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in adults with moderate to severe atopic dermatitis who were also on background topical therapy.

Pfizer Inc. announced that given the unique circumstances of the COVID-19 pandemic and Pfizer’s responsibility to prioritize the health and safety of colleagues and invited guests, the company will reschedule its planned March 31, 2020 Investor Day for a later date..

Roivant Sciences today announced that it has engaged with regulators in the United States, Europe, and Asia to rapidly advance the clinical development of gimsilumab for the treatment of acute respiratory distress syndrome (ARDS) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

In response to the serious challenges posed by the Coronavirus/COVID-19 pandemic, Blue Cross Blue Shield of Massachusetts announced it will cover all medically necessary covered services, via phone or virtually, at no cost to members, effective retroactively to March 16, 2020.